Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

Abstract The poly(ADP‐ribose) polymerase‐1/2 inhibitor veliparib is active against tumors deficient in homologous DNA damage repair. The pharmacokinetics and safety of veliparib extended‐release (ER) were evaluated in patients with advanced solid tumors. This phase I study assessed veliparib‐ER up t...

Descripció completa

Dades bibliogràfiques

Autors principals:	Theresa L. Werner, Jasgit Sachdev, Elizabeth M. Swisher, Martin Gutierrez, Muaiad Kittaneh, Mark N. Stein, Hao Xiong, Martin Dunbar, Danielle Sullivan, Philip Komarnitsky, Mark McKee, Antoinette R. Tan
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2018-06-01
Col·lecció:	Cancer Medicine
Matèries:	BRCA breast carcinoma extended‐release formulation ovarian carcinoma PARP inhibitor veliparib
Accés en línia:	https://doi.org/10.1002/cam4.1488
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!